News FDA gives green light to Chiesi's Lamzede Chiesi scores milestone US FDA approval for first AM enzyme replacement therapy, Lamzede.
News FDA starts review of first drug for alpha-mannosidosis, from... The FDA has started a priority review of Chiesi 's velmanase alfa, an enzyme replacement therapy for lysosomal storage disease (LSD) alpha-mannosidosis, with a decision expected in the firs
News NICE guidance calls for quicker diagnosis of PMOS Women with polyendocrine metabolic ovarian syndrome (PMOS) should be diagnosed sooner and be offered an annual review, according to new NICE guidance.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
